Compass Therapeutics, Inc.

For the period ended Mar 31, 2025. Filed May 8, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 8, 2025

CMPX$0.84+0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets (Unaudited)

Condensed Consolidated Balance Sheets

(In thousands, except par value)

	March 31, 2025 (unaudited)	December 31, 2024 (Note 1)
Assets
Current assets:
Cash and cash equivalents	$41,048	$43,483
Marketable securities	71,587	83,239
Prepaid expenses and other current assets	11,510	6,029
Total current assets	124,145	132,751
Property and equipment, net	231	353
Operating lease, right-of-use ("ROU") asset	6,507	6,731
Restricted cash	568	568
Total assets	$131,451	$140,403
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$1,577	$2,249
Accrued expenses	13,214	6,287
Operating lease obligations, current portion	109	338
Total current liabilities	14,900	8,874
Operating lease obligations, long-term portion	6,272	6,296
Total liabilities	21,172	15,170
Commitments and contingencies (Note 7)
Stockholders' equity:
Common stock, $0.0001 par value: 300,000 shares authorized; 138,282 and 137,820 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	14	14
Additional paid-in-capital	491,391	489,692
Accumulated other comprehensive income	190	210
Accumulated deficit	(381,316)	(364,683)
Total stockholders' equity	110,279	125,233
Total liabilities and stockholders' equity	$131,451	$140,403

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.